Nearly one third of patients with advanced melanoma saw tumors disappear completely after receiving TIL therapy plus pembrolizumab immunotherapy
Results from a clinical trial have revealed nearly one third (29.2 percent) of patients with advanced melanoma saw their tumors disappear completely on scans after receiving lifileucel TIL therapy alongside an immune checkpoint inhibitor, pembrolizumab, as a first-line treatment.
Read original article on The Medical News →Related news
-
Creating 'satellite maps' of thousands of proteins across tissue could transform drug therapies
United Kingdom
-
A consultant is going viral for exposing the cringe-worthy DMs bosses send employees
United States
-
Your Positive Weekly Horoscope: ‘Free Will Astrology’ by Rob Brezsny
United Kingdom
-
Ebola vaccine trial begins in DR Congo
United Kingdom
-
Kenya announces 2nd Ebola death, a close relative of the first patient
United Kingdom
-
Investigational vaccine generates immune response to KRAS mutations in pancreatic cancer study
United Kingdom
-
Good News in History, October 24
United Kingdom
-
Newly discovered protein controls the space between mitochondrial membranes
United Kingdom